|
|
|
Google Links to Dr. James Haim Bicher and/or Valley Cancer Institute
Dr. Haim I. Bicher last publish paper:
Dr. Haim Bicher (James I. Bicher), founder of Valley Cancer institute, recently published a very advance (for it's time) paper, in the Deutsche Zeitschrift für Onkologie (German Journal of Oncology)
Dr. Haim I. Bicher , President of Valley Cancer Institute. Dr. James Bicher last publications: 1. Bicher HI MD. Protracted Thermoradiotherapy, treating to effect with objective end points. Proceedings of the XXV ICHS Destin, Florida, USA, October 16th-19th, 2002
2. Bicher HI MD, Mitagvaria NP PhD, Nebieridze MI MD. Local Hyperthermia treatment results in significant morphological changes in rats’ brain tissue. Proceedings of the XXVI ICHS Shenzhen, China, September 10th-12th, 2004.
3. Bicher HI MD. Thermoradiotherapy Treatment of malignant tumors. Fractionation regime and objective end points. An update. Proceedings of the XXVI ICHS Shenzhen, China, September 10th-12th, 2004.
4. Bicher HI MD., Al-Bussam N MD; Wolfstein, RS. M.D Thermoradiotherapy with curative intent – breast, head and neck and prostate tumors. Proceedings of the XXVII ICHS Florence, Italy, October 27th – 28th, 2005.
5. Bicher HI MD., Al-Bussam N MD; Wolfstein, RS. M.D Thermoradiotherapy with curative intent – breast, head and neck and prostate tumors. Deutsche Zeitschrift für Onkologie (German Journal of Oncology) 2006, 38: 116-122.Haim Bicher, M.D., Haim Bicher, M.D., Haim Bicher, M.D., Haim Bicher, M.D. Paper presented by Dr. James I. Bicher in the Society for Thermal Medicine, June 2006. A Method of Curative Thermoradiotherapy in Superficial Tumors; Breast, Head and Neck, and Prostate Haim I. Bicher, M.D., Nazar Al-Bussam, M.D. and Ralph S. Wolfstein, M.D. Valley Cancer Institute, Los Angeles, California U.S.A.
Objective: To evaluate the effectiveness of hyperfractionated thermoradiotherapy (HTRT) in patients suffering from early stage cancers of the breast cancer, head and neck cancer and prostate cancer that refuse conventional radiation surgery or chemotherapy. Response rates and survival were determined using objective end points. (MRI, MRS, PET scan and tumor markers). Material and Methods: Fractionation used involved daily hyperthermia treatments in conjunction with each radiation fraction. Radiation daily doses are progressively decreased from 180 to 100 cGy resulting in protracted treatment time that decreases the isoeffect biological equivalent dose by 15% to 25%. This decrease is compensated by the increased number of hyperthermia fractions which potentiates each radiation dose. Treatment is continued until an objective complete response is attained, or failure determined. 40 breast cancer patients, 27 head and neck cancer patients, and 18 prostate cancer patients were treated with a follow up of two to five years. All patients were early stage (less than III). Results: Complete response rates were 82% for breast cancer patients, 88% for head and neck cancer, and 93% for prostate cancer patients. Projected 5 year survival rates were 80% for breast cancer patients, 88% for head and neck cancer, and 87% for prostate cancer patients. Side effects were less than with curative radiation therapy alone. No Grade IV toxicity (Common Toxicity Criteria) was observed. Conclusion: Protracted
hyperfractionation of daily thermoradiotherapy decreases the side effects of
radiation therapy, allows treating to effect using objective end point
parameters, accomplishes a high percentage of complete responses and a high
5-year survival rate in the 80-90% range in early superficial tumors. It can be
considered as potentially curative in Stage I-II breast cancer, head and neck
cancer and prostate cancer when used and researched as such. Haim Bicher, M.D., Haim Bicher, M.D., Haim Bicher, M.D., Haim Bicher, M.D. You are visitor No.:
Search Engine Optimization by SeOS |
